The largest database of trusted experimental protocols

14 protocols using plenti giii cmv gfp 2a puro

1

Lentiviral Vector Construction and Knockdown

Check if the same lab product or an alternative is used in the 5 most similar protocols
pLKO.1 puro (Addgene plasmid #8453; http://n2t.net/addgene:8453; RRID:Addgene_8453), pLKO.1 hygro (Addgene plasmid #24150; http://n2t.net/addgene:24150; RRID:Addgene_24150), pCMV-VSV-G (Addgene plasmid #8454; http://n2t.net/addgene:8454; RRID:Addgene_8454), and pCMV-dR8.2 dvpr (Addgene plasmid #8455; http://n2t.net/addgene:8455; RRID:Addgene_8455) were a gift from Prof. Bob Weinberg [42 (link)]. The human LPIAT1-containing lentiviral vector (pLenti-GIII-CMV-GFP-2A-Puro) was purchased from Applied Biological Materials Inc. The ACSL3 and LPIAT1 shRNAs were obtained as bacterial glycerol stock from Sigma-Aldrich and the sequence of interest was subcloned into the pLKO-puro backbone or into pLKO-hygro (for the combination studies with LPIAT1 overexpression) plasmids after digestion with AgeI/EcoRI. The final shRNA constructs were confirmed with sequencing.
+ Open protocol
+ Expand
2

Lentiviral Transduction of T Cells and Stem Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lentiviral constructs encoding control shRNA-GFP (SHC016V0718127MN) or ZFYVE21 shRNA-GFP (TRCN0000436194) constructs were purchased from Sigma-Aldrich. Lentiviral constructs encoding ZFYVE21-GFP (pLenti-GIII-CMV-GFP-2A-Puro) were purchased from Applied Biological Materials. CD4+CD45RO+ T cells (5×104 cells per well) were electroporated with 2μg of the plasmids above according to the manufacturer’s specifications (Amaxa, #VPA-1002) using the Nucleofector II device (Amaxa). Seventy-two hours later, for a total of 4 d in culture, T cells were washed and restimulated with plate-bound anti-CD3 (1μg/mL) and treated as indicated in the text. Lentivirus containing the constructs above were used to infect 1×105 human CD34+ stem cells for 8 hrs. The next day, transduced GFP+ stem cells were FACS-sorted and intrahepatically injected into sublethally irradiated (180 cGy) 1–3dy old female NSG (Jackson, #00557) pups. Nine-to-twelve weeks later, mice were bled and human Tmem were analyzed as indicated in the text. In certain experiments, 8×106 PBMCs from the mice above were passively transferred i.p. into adult 6–12-week-old SCID/bg hosts containing human artery segments implanted into the infrarenal position of the descending aorta. Four weeks later, grafts and host sera were harvested for analysis.
+ Open protocol
+ Expand
3

Lentiviral Expression of PPM1A Variants

Check if the same lab product or an alternative is used in the 5 most similar protocols
Murine PPM1A WT, R174G, and D239N were sub-cloned into pLenti-GIII-CMV-GFP-2A-Puro (Applied Biological Materials, Richmond, BC, Canada). For lentiviral package plasmids, we used pMDLg/pRRE and pRSV/REV, while pLV-VSVG was used as an envelope plasmid (Addgene, #12251, #12253, #82724). HEK-293T cells were transfected with each lentiviral vector, packaging plasmids, and envelope plasmid under 5:2:2:1 ratio. Produced lentivirus from media were infected into 3T3-L1 adipocytes with polybrene (Sigma-Aldrich, St. Louis, MO, USA).
+ Open protocol
+ Expand
4

Lentiviral Transduction of UCP2 in Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
UCP2 (TRCN0000060144) or scramble shRNAs in the pLKO lentiviral vector were purchased (Sigma). The cDNA for UCP2 cloned into a lentiviral vector (pLenti-GIII-CMV-GFP-2A-Puro) with CMV promoter were obtained from Applied Biological Materials (BC, Canada). Cells were sub-cultured at 1.0 × 104 cells/well into 96-well plate. Incubate 18–20 hours at 37°C in a humidified incubator in an atmosphere of 5% CO2. The viral supernatant was then added into cells at a multiplicity of infection (MOI) of 10. After 48–72 h of incubation, the cell culture medium was changed with 2 μg/ml puromycin. Images of the cells expressing GFP were captured under a phase contrast microscope.
+ Open protocol
+ Expand
5

Overexpression of SNAI1 in BECs

Check if the same lab product or an alternative is used in the 5 most similar protocols
For the OE of SNAI1, we used the human SNAI1 lentiviral vector pLenti-GIII-CMV-GFP-2A-Puro (Applied Biological Materials, Viking Way Richmond, BC, Canada). Lentiviral particles were produced by co transfection of sub-confluent HEK293T cells with the SNAI1 plasmid or the pLenti-GIII-CMV-GFP-2A-Puro empty vector as a transfer vector with packaging plasmids (pMDLg/pRRE, pRSV Rev, pMD2.G)33 (link) using calcium phosphate as transfection reagent. Infection-competent lentiviral particles were collected 48 h after transfection and the supernatant was centrifuged to remove cell debris. BECs were transduced with the SNAI1-expressing lentivirus. Forty-eight hours after transduction, SNAI1-expressing cells were selected by puromycin treatment (2 µg/ml).
+ Open protocol
+ Expand
6

Lentiviral Transduction of FZD5 in MS1 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
MS1 cells were transfected with pLenti-GIII-CMV-GFP-2A-Puro (Applied Biological Materials Inc., Richmond, BC, Canada) alone (control) or with a FZD5 sequence [21 (link)] following the manufacturer’s protocol (Applied Biological Materials Inc.). Briefly, 5×104 cells/well were incubated overnight in complete medium containing DMEM with 10% FBS (ATCC®, Manassas, VA, USA). The following day, the medium was replaced by fresh complete medium mixed with polybrene (8 μg/mL; Millipore, Danvers, MA, USA), ViralPlus Transduction Enhancer G698 (1:100; Applied Biological Materials Inc.), and GFP or FZD5/GFP lentivirus. After an overnight incubation, the medium was removed and the cells were incubated for another night in fresh complete medium. The following day, puromycin (2 μg/ml; Gibco, Grand Island, NY, USA) was added to the medium. The expression of FZD5 was verified by western blot and GFP expression was verified using the fluorescent EVOS microscope (Life Technologies, Carlsbad, CA, USA).
+ Open protocol
+ Expand
7

Overexpression and knockdown of GRHL2 and ZEB1 in cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
GRHL2-targeting shRNA (TRCN0000015810 and TRCN0000015812) and negative control plasmids—Luciferase shRNA and non-targeting shRNA (SHC007, SHC016) were purchased from Sigma. Plasmids were incubated with Lentiviral Packaging Mix (SHP001, Sigma) and Fugene 6 (Roche) before addition to 293T cells. Viral supernatants were harvested to infect cells with the addition of 8 μg/ml polybrene (Sigma). After 48 h, infected cells were selected by puromycin (4 to 7 μg/ml). For ZEB1 overexpression, plasmid pCMV6-AC-GFP-ZEB1 generated from pCMV6-Entry-ZEB1 (RC217704, Origene) was used. Transfected cells were selected by G418 (Life Technologies) at 300 μg/ml, and three single clones (one ZEB1-low, two ZEB1-high) were picked. For GRHL2 overexpression, pLenti-GIII-CMV-GFP-2A-Puro was purchased from Applied Biological Materials. shRNA-resistant GRHL2* with four silent mutations was generated using Quick Change II XL Site-Directed Mutagenesis kit (Stratagene). For overexpression of mature miRNAs, microRNA mimics (HMC0002, HMI0357, HMI0350, HMI0352, HMI0359; Sigma) were transfected into cells by HiPerfect® transfection reagent (Qiagen).
+ Open protocol
+ Expand
8

Transfection of HUVECs and Eca-109 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
For transient transfection, HUVECs were transfected with a miR-181b-5p mimic, an inhibitor, or a negative control (Applied Biological Materials, Canada), respectively. HUVECs were transfected with siRNAs targeting PTEN, PHLPP2, or a negative control RNA duplex (GenePharma, China) using Lipofectamine 3000 (Invitrogen, USA) according to the manufacturer’s instructions. The siRNA sequences were listed in Table S5. For stable transfection, Eca-109 cells were transfected with a miRCURY LNA miR-181b-5p mimic, an inhibitor, or a negative control (Exiqon, Denmark), respectively. For overexpression, the full-length complementary DNAs (cDNAs) of PTEN and PHLPP2 were synthesized and cloned into the lentiviral expression vector of pLenti-GIII-CMV-GFP-2A-Puro (Applied Biological Materials, Canada), whereas an empty lentiviral vector was used as a control. The lentiviral vector HUBLV-GFP-Puro-Luc (HANBIO, China) was cloned into Eca-109 cells for tail vein metastasis assay. Transfected cells were selected with 1 μg/mL puromycin for 2 weeks. The transfection efficiency was monitored by the GFP.
+ Open protocol
+ Expand
9

Lentiviral Prom1 Overexpression Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
The wild-type (WT) Prom1 lentiviral construct (pLenti-GIII-CMV-GFP-2A-Puro; (NM_001145848.1) was obtained from Applied Biological Materials, Inc., expressing Prom1 under the control of CMV promoter. Plasmids were amplified using the Qiagen Plasmid maxi prep kit following the manufacturers instructions. Ten micrograms Prom1 plasmid and the empty GFP control plasmid were packaged in human 293FT cells and purified through ultracentrifugation at the Viral Vector Core laboratory as described previously.30 (link)
+ Open protocol
+ Expand
10

Overexpression of Rat Neu3 in H9c2 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
H9c2 were plated at a density of 1 × 105 cells and transfected with a Rat Neu3 Lentiviral Vector (pLenti-GIII-CMV-GFP-2A-Puro) (Applied Biological Materials, Richmond, BC, Canada) according to the ViaFect™ Transfection Reagent (Promega Corporation, Madison, WI, USA) manufacturer’s protocol, after reaching 90% confluency. Transfected cells were selected using 10 mg/mL puromycin (Invivogen, San Diego, CA, USA) and the clone with the highest Neu3 expression and activity was employed for the further experiments.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!